Dynamics of T cell subpopulations and plasma cytokines during the first year of antineoplastic therapy in patients with breast cancer: the BEGYN-1 study (2025) Kaiser E, Weber R, Hirschstein M, Mazid H, Kapps EMS, Hans MC, Bous M, et al. Journal article Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (Breast Cancer Research, (2022), 24, 1, (69), 10.1186/s13058-022-01567-3) (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BA, Becher H, Blomqvist C, et al. Journal article, Erratum Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, et al. Journal article Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment (2021) Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, et al. Journal article Human leucocyte antigen class i in hormone receptor-positive, HER2-negative breast cancer: Association with response and survival after neoadjuvant chemotherapy (2019) Sinn BV, Weber KE, Schmitt WD, Fasching P, Symmans WF, Blohmer JU, Karn T, et al. Journal article Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth (2018) Mao SPH, Park M, Cabrera RM, Christin JR, Karagiannis GS, Oktay MH, Zaiss DMW, et al. Journal article